Global Human Reproductive Technologie Industry

NEW YORK, Jan. 11, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Human Reproductive Technologies in US$ Million by the following Product Segments: Contraceptive Technologies, and Infertility Technologies. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 102 companies including many key and niche players such as -

Actavis, Inc.
Ansell Limited
Agile Therapeutics, Inc.
Bayer HealthCare
Church & Dwight Co., Inc.



Read the full report: http://www.reportlinker.com/p03549668-summary/view-report.html



I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 A Prelude to Human Reproductive Technologies II-1 In-Vitro Fertilization (IVF) - The Leading Infertility Treatment II-1 Table 1: IVF Practice by Region (2014): Percentage Breakdown of No. of IVF Cycles Performed per year for Global Regions (includes corresponding Graph/Chart) II-2 Contraceptives.............. II-3

2. MARKET SEGMENTATION..............II-5 Infertility - Overview..............II-5 Table 2: Average Age of First-time Mothers by Year and Country (1970 and 2006) (includes corresponding Graph/Chart) II-5 Causes.............. II-5 Table 3: Infertility Causes in the US by Gender: Percentage Share of Female, Male, Female-Male Combined, and Unknown Factors (includes corresponding Graph/Chart) II-6 Treatment.............. II-6 Fertility Enhancement Drugs..............II-7 Commonly Used Fertility Drugs..............II-7 Major Brands of Fertility Enhancement/ Ovulation-Induction Drugs.............. II-7 Gonadotropin Therapy..............II-8 Major Gonadotropin Drugs Used Worldwide II-8 Assisted Reproductive Technology (ART) II-9 Table 4: ART Therapy by Gamete Source (2014): Percentage Share Breakdown of Number of Procedures using fresh non-donor eggs, fresh donor eggs, frozen non-donor eggs, frozen donor eggs, and Embryo/Egg Banking (includes corresponding Graph/Chart)..............II-9

Table 5: Cumulative Success Rates of IVF by Number of Cycles: Percentage of Success with one, two & three cycles (includes corresponding Graph/Chart) II-9

Table 6: IVF Success Rates by Age Group (2014): No. of IVF Cycles Performed, and Percentage of Successful Pregnancies and Live Births for Women <35, 35-37, 38-40, 41-42, 43-44, and >44 Yrs (includes corresponding Graph/Chart) II-10 Costs.............. II-10 Table 7: Average Costs of Different ART Methods II-11

Table 8: Average Expenditure Involved for Different Types of Adoption in the US..............II-11 Key Growth Drivers/Trends of the Infertility Market II-11 Increasing Maternal Age Leading to Infertility Issues II-11 Table 9: Mounting Infertility Rates by Age: Rate of Infertility for Women in 15-29, 30-34, 35-39, and 40-44 Age groups (includes corresponding Graph/Chart) II-11 Higher Rates of Obesity Adversely Impacting Fertility II-12 Table 10: Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population by Leading Countries (includes corresponding Graph/Chart)..............II-12 Cultural Shifts and Society Acceptance of Same-sex Marriage Boost ART.............. II-12 Table 11: Increase in Same-sex Marriages in the US: Number Estimates of Homosexual Married Couples in 2008, 2010, 2011, 2012 & 2013 (includes corresponding Graph/Chart) II-13 Medical Tourism on the Rise..............II-13 Market Restraints..............II-13 Variations in Regulations..............II-13 Ethical, Religious and Legal Challenges II-14 Competitive Landscape..............II-15 CONTRACEPTIVES.............. II-16 Table 12: Global Contraceptives Market by Segment (2013): Percentage Share Breakdown of Value Sales by Segment - Oral Contraceptives, Condoms, Implants/Injections, and Others (includes corresponding Graph/Chart) II-16 Major Brands of Oral Birth Control Pills Worldwide by Type and Composition.............. II-17 Growth Drivers.............. II-18 Market Trends.............. II-18 Unmet Contraceptive Needs in Underdeveloped Countries II-18 Major Hindrances for Widespread Usage of Condoms II-18 Increasing Awareness of STDs Creates Additional Demand for Condoms.............. II-19 Drospirenone - Controversial Ingredient in Oral Contraceptive Pills.............. II-19 Contraceptive Manufacturers Focus on Extensive R&D II-20 Innovative Condom Promotion Strategies Enhance Product Appeal II-20 Female Condoms: Empowering the Woman of Today II-21 Multifunctional Modern Contraceptives Make a Foray II-21 UNFPA Boosts the Contraceptive Market in Emerging Economies II-21 Emergency Contraception Receives Encouragement from Government II-22 Public Health Organizations Spur Condoms Use II-23 Favorable Demographic, Social and Economic Trends Strengthens Market Prospects..............II-23 Table 13: World Population (2012): Population and Percentage Share Breakdown by Age Group - Below 15 Years, 15-64 Years, Above 65 Years (includes corresponding Graph/Chart) II-24 Competition in the Condoms Market II-24 Table 14: Leading Players in the Global Condoms Market (2013): Percentage Market Share by Revenue for Ansell, Church & Dwight, Okamoto, Reckitt Benckiser, and Others (includes corresponding Graph/Chart)..............II-25

Table 15: Durex' Dominance Worldwide (2013): Market Shares in Select Regions (includes corresponding Graph/Chart) II-26

3. INNOVATIONS IN THE HUMAN REPRODUCTIVE TECHNOLOGIES SPACE II-27 Time-lapse Technology Allows Undisturbed Embryo Monitoring II-27 Breakthrough Molecular Research to Make Male Contraception a Reality.............. II-28 Vasalgel - Revolutionary Male Contraceptive Polymer and Pill II-28 Prediction of Chromosomal Abnormalities in Cell-1 Stage IVF Embryos.............. II-29 ICSI Results not Affected by Spermatozoa Source/Etiology II-30 Autologous Mitochondrial Transfer for Enhanced IVF Success II-30 PGD Assesses Risk of mtDNA Transfer to Child II-31 Sunshine Found to Boost IVF Outcomes II-31 Newer Innovations in the Contraceptive Market II-31 Remote-Controlled Female Contraceptives II-32 ART Bringing a Paradigm Shift in the Field of Cellular Biology II-32 INVOcell Fosters Growth for the ART Industry II-32 RISUG Technique Gains Recognition II-33

4. TECHNOLOGY OVERVIEW..............II-34 Reproduction: Preface..............II-34 Male Reproductive System..............II-34 Female Reproductive System..............II-34 Dynamics of Reproductive Endocrinology II-35 Human Reproductive Technologies..............II-36 Male/Female Infertility: Causes & Treatment II-36 Fertility Technologies and Procedures II-37 Assisted Reproductive Technology (ART) II-37 Table 16: Increasing ART Treatments: No. of ART Treatment in 1980, 1990, 2000, and 2010 (includes corresponding Graph/Chart).............. II-37 In-Vitro Fertilization (IVF)..............II-37 Ovarian Stimulation:..............II-38 Egg Retrieval:..............II-38 Fertilization:..............II-38 Embryo Transfer:..............II-39 Advantages of IVF..............II-39 Embryo Screening for Inherited Diseases II-39 Benefits for Single Women/Homosexual Couples II-40 Use of Additional Embryos..............II-40 Disadvantages of IVF..............II-40 Multiple Pregnancies..............II-40 Associated Side-Effects..............II-40 Ectopic Pregnancy..............II-40 Perinatal Outcomes for Singletons II-41 Low Success Rate..............II-41 Intrauterine Insemination (IUI) II-41 Intracytoplasmic Sperm Injection (ICSI) II-41 Other Fertility Technologies and Advancements II-42 Cost-Effectiveness of ART..............II-42 Medical Risks Associated with ART II-42 Ethical Issues Associated with ART II-43 Third-Party Assisted ART..............II-44 Sperm Donation..............II-44 Egg Donation.............. II-44 Surrogates or Gestational Carriers II-44 CONTRACEPTION - OVERVIEW..............II-44 User Involvement.............. II-45 Popular Devices and Methods of Contraception II-45 Oral Contraceptive Pill..............II-45 Intrauterine Devices..............II-47 Barrier Contraceptives..............II-48 Condoms - Types, Benefits, and Risks II-48 Table 17: Condom Search Volume by Brand (2015): Percentage Share of Online Search Volumes for Leading Brands (includes corresponding Graph/Chart) II-50 Transdermal Contraceptives..............II-50 Transdermal Patch..............II-50 Vaginal Ring.............. II-51 Subdermal Implants..............II-51 Comparative Analysis of Contraceptive Implants II-51 Emergency Contraception..............II-52 Progestin Pills:.............. II-52 Ulipristal acetate:..............II-52 Combined Pills:..............II-52 Paragard® Copper-T IUD:..............II-52 Comparison of Various Forms of Hormone- based and Non- hormonal Emergency Contraception II-53 Table 18: Effectiveness of Contraceptive Methods: Percentage of Unwanted Pregnancy Resulting from Various Contraceptive Means (includes corresponding Graph/Chart) II-53 Historical Overview of Human Genetic and Reproductive Technologies.............. II-54

5. PRODUCT LAUNCHES/APPROVALS..............II-56 Agile Announces USPTO Patent Allowances for New Contraceptive Regimens.............. II-56 Genea Biomedx Receives CE Certification for Gavi® and Geri® II-56 Agile Announces Patent Issuance for Twirla® Patch II-56 Teva Launches Generic Contraceptive Junel® Fe 24 II-56 Auxogyn's Eeva™ System Receives FDA Clearance II-56 Lupin Receives FDA Approval to Market Generic Lutera® (US) II-57 EPO to Grant Patent to Auxogyn's Eeva™ Test II-57

6. RECENT INDUSTRY ACTIVITY..............II-58 CooperSurgical Acquires Reprogenetics II-58 Genea, Merck, and Illumina Form the Global Fertility Alliance II-58 Genea Biomedx and Merck Sign Fertility Collaboration Agreement II-58 Auxogyn and Fertility Authority Merge to Form Progyny II-58 Collaboration Agreement to Expand Access to Pfizer's Sayana® Press.............. II-58 Reprogenetics Enters Into Partnership with Illumina II-58 Cipla Medpro Enters into Collaboration with Teva Pharmaceuticals II-59 Genea Starts European Manufacturing Operations II-59 Ferring Pharmaceuticals Partners with Roche II-59 OPMEDIC Group Becomes Privately Owned II-59 Fertility Group Genea Creates IVF Technology Company Genea Biomedx.............. II-59 Auxogyn Enters Into Partnership with Valencia Infertility Institute.............. II-59 Agile Enters Into US$15 Million Financing Agreement with Oxford Finance.............. II-59

7. FOCUS ON SELECT GLOBAL PLAYERS..............II-60 Actavis, Inc. (US)..............II-60 Ansell Limited (Australia)..............II-60 Agile Therapeutics, Inc. (US)..............II-61 Bayer HealthCare (Germany)..............II-61 Church & Dwight Co., Inc. (US) II-61 Cipla Limited (India)..............II-62 CellCura ASA (Norway)..............II-62 Cook Medical (US).............. II-63 CooperSurgical (US).............. II-63 Ferring Pharmaceuticals (Switzerland) II-63 Fuji Latex Co., Ltd. (Japan)..............II-64 Genea Biomedx (Australia)..............II-64 Merck KGAA (Germany)..............II-64 Okamoto Industries (Japan)..............II-65 Pfizer Inc. (US).............. II-65 Progyny, Inc. (US)..............II-65 Reckitt Benckiser Group Plc. (UK) II-66 Sanofi (US).............. II-66 Teva Pharmaceutical Industries Ltd. (Israel) II-67 The Female Health Company (US) II-67

8. GLOBAL MARKET PERSPECTIVE..............II-68 Table 19: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............II-68

Table 20: World Historic Review for Human Reproductive Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. II-69

Table 21: World 14-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-70

Table 22: World Recent Past, Current & Future Analysis for Human Reproductive Technologies by Technology - Contraceptive and Infertility Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) II-71

Table 23: World Historic Review for Human Reproductive Technologies by Technology - Contraceptive and Infertility Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)..............II-72

Table 24: World 14-Year Perspective for Human Reproductive Technologies by Technology - Percentage Breakdown of Value Sales for Contraceptive and Infertility Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-73

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 United States: The Leading Market for Human Reproductive Technologies.............. III-1 Pill Continues as One of the Most Popular Forms of Contraception.............. III-1 Table 25: The US Oral Contraceptives Market by Leading Brand (2013): Percentage Market Share Breakdown of Leading Oral Contraceptive Brands in Drugstores (includes corresponding Graph/Chart)..............III-2 Condoms Market - Highly Concentrated III-2 Table 26: The US Condoms Market by Leading Player (2014): Percentage Market Share Breakdown for Ansell America, Church and Dwight Co., Reckitt Benckiser and Others (includes corresponding Graph/Chart) III-2

Table 27: The US Condoms Market by Leading Player (2014): Percentage Share Breakdown of Drugstore Sales for Ansell America, Church and Dwight Co., Reckitt Benckiser, and Others (includes corresponding Graph/Chart) III-3 Domestic Condom Players Face Tough Competition from Foreign Brands.............. III-3 Delayed Childbearing Spells Fortune for the Fertility Industry III-4 Table 28: The US Birth Rates by Maternal Age and Year: Rate of Birth in Women in the Age groups <20, 20-29, 30-34, and 35-39+ for the Years 2000, 2006, 2011 & 2013 (includes corresponding Graph/Chart)..............III-4 Increasing Numbers of Female IVF Users III-5 Rise in Successful Births from IVF, Multiple Births Decline Due to Modern Methods..............III-5 Bill Passed for Same-sex Couples to Avail IVF Treatments III-6 Emergency Contraception Pills: Access at Pharmacies, Reimbursement, and State wise Policies III-6 List of State wise Policies on Requiring ERs to Dispense Emergency Contraception and Related Services III-7 Women's Awareness and Usage of EC III-7 Table 29: Emergency Contraceptive Awareness and Usage Among US Women by Age Group (2015): Percentage of Women who heard of EC & Percentage of Women who used EC (includes corresponding Graph/Chart)..............III-7 Skyla IUD - Boon for Younger Women III-8 Lack of Regulations - Blessing or Drawback? III-8 Product Launches..............III-9 Strategic Corporate Developments III-10 Select Key Players..............III-11 B.Market Analytics..............III-15 Table 30: The US Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-15>

Table 31: The US Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-16

2. CANADA.............. III-17 A.Market Analysis.............. III-17 Canada Lags Behind in Reproductive Technology III-17 Compensation Banned for Surrogacy III-17 Strategic Corporate Development III-18 OPMEDIC Group Inc. - A Key Player III-18 B.Market Analytics..............III-19 Table 32: Canadian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-19

Table 33: Canadian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-20

3. JAPAN.............. III-21 A.Market Analysis.............. III-21 Oral Contraceptives Not Favored III-21 Condoms Usage Continues to Soar III-21 Major Condom Brands in Japan III-22 Crown and Beyond Seven..............III-22 Kimono Condoms.............. III-22 Select Key Players..............III-22 B.Market Analytics..............III-23 Table 34: Japanese Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-23

Table 35: Japanese Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-24

4. EUROPE.............. III-25 A.Market Analysis.............. III-25 Table 36: European Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment - Condoms, Implants/Injections, Oral Contraceptives and Others (includes corresponding Graph/Chart) III-25 National Testing Labs Join Hands to Find Solutions for Improved Quality of Condom Testing III-25 B.Market Analytics..............III-27 Table 37: European Recent Past, Current & Future Analysis for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-27

Table 38: European Historic Review for Human Reproductive Technologies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-28

Table 39: European 14-Year Perspective for Human Reproductive Technologies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-29

4a. FRANCE.............. III-30 Market Analysis.............. III-30 Table 40: French Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-30

Table 41: French Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-31

4b. GERMANY.............. III-32 A.Market Analysis.............. III-32 Key Players.............. III-32 B.Market Analytics..............III-33 Table 42: German Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-33

Table 43: German Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-34

4c. ITALY.............. III-35 Market Analysis.............. III-35 Table 44: Italian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-35

Table 45: Italian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-36

4d. THE UNITED KINGDOM..............III-37 A.Market Analysis.............. III-37 Contraceptives - A Mature Market III-37 Table 46: Condom Usage in the UK (2013): Breakdown of Usage Rate by Gender and Age (includes corresponding Graph/Chart) III-37 Durex - The Dominant Brand..............III-38 UK Government Approves Mitochondrial Replacement III-38 Strategic Corporate Development III-39 Reckitt Benckiser Group Plc. - A Key Player III-39 B.Market Analytics..............III-40 Table 47: The UK Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-40

Table 48: The UK Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-41

4e. SPAIN.............. III-42 Market Analysis.............. III-42 Table 49: Spanish Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-42

Table 50: Spanish Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-43

4f. RUSSIA.............. III-44 Market Analysis.............. III-44 Table 51: Russian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-44

Table 52: Russian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-45

4g. REST OF EUROPE.............. III-46 A.Market Analysis.............. III-46 Greece: Fertility Tourism to Mitigate Financial Crisis III-46 Strategic Corporate Development III-46 Key Players.............. III-46 B.Market Analytics..............III-47 Table 53: Rest of European Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-47

Table 54: Rest of European Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)..............III-48

5. ASIA-PACIFIC.............. III-49 A.Market Analysis.............. III-49 Government Incentives to Prevent "Low Fertility Trap" III-49 Developing Asian Countries Offer Significant Growth Opportunities.............. III-49 Table 55: China and India Lead Global Population (July 2013): Table Depicting China and India's Huge Population Vis-a-vis Other Countries' Population (in Million) by Age Group (includes corresponding Graph/Chart) III-50 Rising HIV/AIDS Prevalence..............III-50 Table 56: Top Twelve Countries in Asia-Pacific with the Highest HIV Incidence (2012) (includes corresponding Graph/Chart).............. III-51 Asia-Pacific Contraceptive Market III-52 Table 57: Asia-Pacific Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Region - China, India and Rest of Asia-Pacific (includes corresponding Graph/Chart)..............III-52

Table 58: Asia-Pacific Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment - Condoms, Implants/Injections, Oral Contraceptives, and Others (includes corresponding Graph/Chart) III-52 B.Market Analytics..............III-53 Table 59: Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies by Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-53

Table 60: Asia-Pacific Historic Review for Human Reproductive Technologies by Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-54

Table 61: Asia-Pacific 14-Year Perspective for Human Reproductive Technologies by Region - Percentage Breakdown of Value Sales for China, India, and Rest of Asia-Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).............. III-55

5a. CHINA.............. III-56 A.Market Analysis.............. III-56 An Overview of the Chinese Market for Condoms III-56 Condoms Market Exhibits Unprecedented Growth III-57 Fight against HIV Augurs Well for Condoms Market III-57 Chinese Condom Makers Eyeing Smaller Cities to Spruce up Sales III-57 B.Market Analytics..............III-58 Table 62: Chinese Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-58

Table 63: Chinese Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-59

5b. INDIA.............. III-60 A.Market Analysis.............. III-60 Preferred Destination for Reproductive Medical Tourism III-60 Need for Proper Legislative Framework for Surrogacy and Egg Donation.............. III-60 Indian Condom Market Overview..............III-61 Social Stigmas Continue to Hamper Growth III-61 Male Condom Market Witnesses Growth III-62 Price Cap on Condoms to Dent Premium Condom Market III-62 India Witnesses Decline in Use of Government-Issued Condoms III-62 Opportunities Abound for Female Condoms III-62 NACO's Initiatives Spurs Female Condoms Use III-63 Challenges to Reckon With..............III-63 Usage of Female Condoms Remains a Challenge III-63 Indian Women Fairly Open to the Concept of Oral Contraceptives III-64 Table 64: Indian OTC Contraceptive Pill Market by Brand (2012): Percentage Breakdown of Revenue for Mala-D, Choice, Saheli, Suvidha, Khushi & Others (includes corresponding Graph/Chart).............. III-64 Cipla Limited - A Key Player III-65 B.Market Analytics..............III-65 Table 65: Indian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)..............III-65

Table 66: Indian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-66

5c. REST OF ASIA-PACIFIC..............III-67 A.Market Analysis.............. III-67 Australia.............. III-67 Ban on Commercial Surrogacy III-67 Focus on Acquisitions and Consolidation III-67 Product Approval..............III-67 Strategic Corporate Developments III-68 Genea Biomedx (Australia) - A Key Player III-68 B.Market Analytics..............III-69 Table 67: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-69

Table 68: Rest of Asia-Pacific Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)..............III-70

6. THE MIDDLE EAST & AFRICA..............III-71 A.Market Analysis.............. III-71 Africa.............. III-71 Huge Opportunities in Store for Condom Makers III-71 South Africa.............. III-71 Family Planning Programs: The Key Source for Condoms III-71 Strategic Corporate Development III-72 Teva Pharmaceutical Industries Ltd. (Israel) - A Key Player III-72 B.Market Analytics..............III-73 Table 69: The Middle East & Africa Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-73

Table 70: The Middle East & Africa Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)..............III-74

7. LATIN AMERICA.............. III-75 A.Market Analysis.............. III-75 Market for Female Condoms Still Nascent III-75 Table 71: Latin American Market for Contraceptives (2013): Percentage Share Breakdown of Value Sales by Segment - Condoms, Implants/Injections, Oral Contraceptives and Others (includes corresponding Graph/Chart) III-75 B.Market Analytics..............III-76 Table 72: Latin American Recent Past, Current & Future Analysis for Human Reproductive Technologies by Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-76

Table 73: Latin American Historic Review for Human Reproductive Technologies by Region - Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-77

Table 74: Latin American 14-Year Perspective for Human Reproductive Technologies by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin American Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart).............. III-78

7a. BRAZIL.............. III-79 A.Market Analysis.............. III-79 Role of Condom Social Marketing (CSM) III-79 National Policy.............. III-79 National Regulation..............III-79 B.Market Analytics..............III-80 Table 75: Brazilian Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-80

Table 76: Brazilian Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart).............. III-81

7b. REST OF LATIN AMERICA..............III-82 Market Analysis.............. III-82 Table 77: Rest of Latin American Recent Past, Current & Future Analysis for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-82

Table 78: Rest of Latin American Historic Review for Human Reproductive Technologies Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)..............III-83

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 102 (including Divisions/Subsidiaries - 115)

The United States (28) Canada (3) Japan (3) Europe (34) - France (1) - Germany (11) - The United Kingdom (6) - Italy (3) - Rest of Europe (13) Asia-Pacific (Excluding Japan) (41) Latin America (3) Africa (2) Middle East (1)
Read the full report: http://www.reportlinker.com/p03549668-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

http://www.reportlinker.com